These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 4415920

  • 1. Structure-activity relationships in immunochemistry. 2. Inhibition of complement by benzamidines.
    Hansch C, Yoshimoto M.
    J Med Chem; 1974 Nov; 17(11):1160-7. PubMed ID: 4415920
    [No Abstract] [Full Text] [Related]

  • 2. Irreversible enzyme inhibitors. CLXIV. Proteolytic enzymes. XIV. Inhibition of guinea pig complement by meta-substituted benzamidines.
    Baker BR, Cory M.
    J Med Chem; 1969 Nov; 12(6):1049-52. PubMed ID: 5389146
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of the haemolytic complement activity by derivatives of benzamidine.
    Hauptmann J, Markwardt F.
    Biochem Pharmacol; 1977 Feb 15; 26(4):325-9. PubMed ID: 849323
    [No Abstract] [Full Text] [Related]

  • 4. A comprehensive study on the mechanism of inhibition of serine proteases by benzamidines based on quantitative structure-activity relationship studies.
    Gupta SP, Handa A, Shewade DG.
    Arzneimittelforschung; 1987 Jan 15; 37(1):47-50. PubMed ID: 2952126
    [Abstract] [Full Text] [Related]

  • 5. Comparative inhibition of thrombin, plasmin, trypsin, and complement by benzamidines using substituent constants and regression analysis.
    Coats EA.
    J Med Chem; 1973 Oct 15; 16(10):1102-6. PubMed ID: 4270699
    [No Abstract] [Full Text] [Related]

  • 6. Inhibition of four human serine proteases by substituted benzamidines.
    Andrews JM, Roman DP, Bing DH.
    J Med Chem; 1978 Dec 15; 21(12):1202-7. PubMed ID: 152812
    [Abstract] [Full Text] [Related]

  • 7. Irreversible enzyme inhibitors. 186. Irreversible inhibitors of the C'la component of complement derived from m-(phenoxypropoxy)benzamidine by bridging to a terminal sulfonyl fluoride.
    Baker BR, Cory M.
    J Med Chem; 1971 Sep 15; 14(9):805-8. PubMed ID: 5140007
    [No Abstract] [Full Text] [Related]

  • 8. Structure-activity relationships in immunochemistry. 4. Inhibition of complement by benzylpyridinium ions. On the predictive value of correlation equations.
    Hansch C, Yoshimoto M, Doll MH.
    J Med Chem; 1976 Sep 15; 19(9):1089-93. PubMed ID: 978672
    [No Abstract] [Full Text] [Related]

  • 9. Irreversible enzyme inhibitors. CLII. Proteolytic enzymes. X. Inhibition of guinea pig complement by substituted benzamidines.
    Baker BR, Erickson EH.
    J Med Chem; 1969 May 15; 12(3):408-14. PubMed ID: 5788155
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Irreversible enzyme inhibitors. 180. Irreversible inhibitors of the C'la component of complement derived from m-(phenoxypropoxy)benzamidine and phenoxyacetamide.
    Baker BR, Cory M.
    J Med Chem; 1971 Feb 15; 14(2):119-25. PubMed ID: 5544395
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of serine proteinases by benzamidine derivatives.
    Walsmann P.
    Acta Biol Med Ger; 1977 Feb 15; 36(11-12):1931-7. PubMed ID: 616739
    [Abstract] [Full Text] [Related]

  • 13. Structure-activity relationships in immunochemistry. III. Inhibition of complement by benzyl pyridinium ions.
    Yoshimoto M, Hansch C, Jow PY.
    Chem Pharm Bull (Tokyo); 1975 Feb 15; 23(2):437-44. PubMed ID: 1157202
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of acrosin by benzamidines.
    Stürzebecher J.
    Acta Biol Med Ger; 1981 Feb 15; 40(10-11):1519-22. PubMed ID: 7044006
    [Abstract] [Full Text] [Related]

  • 15. Active site of bovine factor Xa. Characterization using substituted benzamidines as competitive inhibitors and affinity-labeling reagents.
    Robison DJ, Furie B, Furie BC, Bing DH.
    J Biol Chem; 1980 Mar 10; 255(5):2014-21. PubMed ID: 7354070
    [No Abstract] [Full Text] [Related]

  • 16. Effect of C1-inhibitor, benzamidine, and heat treatment on the hydrolytic activity of a subcomponent of the first component of human complement, C1s.
    Takahashi K, Nagasawa S, Koyama J.
    Biochim Biophys Acta; 1980 Jan 11; 611(1):196-204. PubMed ID: 7350917
    [No Abstract] [Full Text] [Related]

  • 17. Novel bis(benzamidino) compounds with an aromatic central link. Inhibitors of thrombin, pancreatic kallikrein, trypsin, and complement.
    Geratz JD, Cheng MC, Tidwell RR.
    J Med Chem; 1976 May 11; 19(5):634-9. PubMed ID: 1271404
    [Abstract] [Full Text] [Related]

  • 18. Structure-activity relationships for the inhibition of acrosin by benzamidine derivatives.
    Parrish RF, Straus JW, Paulson JD, Polakoski KL, Tidwell RR, Geratz JD, Stevens FM.
    J Med Chem; 1978 Nov 11; 21(11):1132-6. PubMed ID: 722718
    [Abstract] [Full Text] [Related]

  • 19. [Free-Wilson analysis of the inhibitory effect of 4-substituted benzamidines on thrombin, plasmin and trypsin (author's transl)].
    Labes D, Hagen V.
    Pharmazie; 1979 Nov 11; 34(9):554-6. PubMed ID: 161622
    [Abstract] [Full Text] [Related]

  • 20. Inactivation of the first component of human complement by m-(o-(2-chloro-5-fluorosulfonylphenylureido)-phenoxybutoxy)benzamidine.
    Bing DH, Mernitz JL, Spurlock SE.
    Biochemistry; 1972 Nov 07; 11(23):4263-8. PubMed ID: 4673057
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.